Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Monoclonal antibody MT2 and anti-immunoglobulins were tested for their ability to discriminate between reactive lymphoid hyperplasia and follicular lymphoma (centroblastic/centrocytic; CB/CC) informalin-fixed and wax-embedded biopsies. The streptavidin biotin peroxidase complex method was used. In 46 of 49 cases of reactive follicular hyperplasia the follicle center cells were unstained by MT2 whereas the mantle zone B cells and interfollicular T cells were positive. In three reactive cases up to 30% of follicle center cells also were stained. In contrast, more than 50% of neoplastic follicle center cells were stained by MT2 in 27 of 62 cases of CB/CC, and light chain restriction was shown in 52 of 62 cases. MT2 staining and/or light chain restriction was seen in 57 of 62 cases. In 106 further cases of non-Hodgkin's lymphoma, MT2 was positive in 59 of 77 B cell lymphomas and 3 of 29 T cell lymphomas. Although not a B cell specific reagent, MT2 is useful in the differential diagnosis of reactive vs. neoplastic follicular lymphoid proliferations but is less sensitive than immunoglobulin stains.
 ...
PMID:A comparison between monoclonal antibody MT2 and immunoglobulin staining in the differential diagnosis of follicular lymphoid proliferations in routinely fixed wax-embedded biopsies. 246 83

Between 1983 and 1993, 3165 cases of non-Hodgkin's lymphoma (NHL) were reported to the West Danish Lymphoma Registry (LYFO). Out of these, 148 (4.7%) were of the CB/CC diffuse subtype according to the Kiel classification. However, in the new European-American NHL consensus classification (REAL, 1994), CB/CC diffuse lymphoma was categorized as a provisional subtype only. In the LYFO material, death-probability curves show a significantly shorter survival in CB/CC diffuse than in CB/CC follicular. In order to detect further possible differences between CB/CC diffuse and other NHL subtypes, a number of clinical parameters at presentation were analyzed in a subset of five types of lymphoma. This subset included 148 cases of CB/CC diffuse, 435 cases of CB/CC follicular, 667 cases of CB diffuse, 202 cases of CC diffuse, and 131 cases of peripheral T-cell lymphoma. Using logistic regression analysis, significant differences could be demonstrated between CB/CC diffuse and the four other subtypes as regards sex ratio, age distribution, and sites of both nodal and extranodal involvement. These findings indicate that CB/CC diffuse has a distinct clinical phenotype and imply the existence of real biological differences between CB/CC diffuse and other subtypes of lymphoma.
 ...
PMID:CB/CC diffuse lymphoma: a distinct subtype of non-Hodgkin's lymphoma? A study of 1593 patients from a Danish population-based registry. Danish LYFO Study Group. 920 35